Is Hyperfine going out of business?

Hyperfine, Inc. (HYPR) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Hyperfine, Inc. (HYPR) scores 36 out of 100 on fundamentals, Speculative / Volatile, based on SEC filing data.

Leading signal: FCF margin: -214.80%

Five questions, kept separate

Survival - Funding dependent

15-21 mo of estimated runway from 2026-06-30, based on $43.5M of cash and short-term investments against $29.1M of annual burn. Adjusted shares outstanding increased 28.4% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Balanced

40.9% net-cash backing support a balanced pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• FCF margin: -214.80%
• Debt / Equity: -0.82x (Net Cash)
• ROIC: -542.77%
• Revenue CAGR (3Y): 25.79%
• Shares dilution YoY: 28.43% (YoY)
• R&D intensity: 86.69%
• Return on Assets: -56.47%
• Debt Maturity Runway: 100% long-term (Long-term focused)
• Revenue Quality: High-quality (DSO -57d, Rev +45%)
• Revenue growth YoY: 44.81% (YoY) - Growth from a low base; sustainability uncertain.
• Asset Growth Velocity: 39.27% YoY (Scaling infra)
• Cash Burn Deceleration: -78.85% QoQ improvement (Worsening)

Read from filings through 2026-08-06.

Price as of 2026-09-07.